Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Beats Revenue Estimates

Crinetics Pharmaceuticals reported a quarterly loss of $1.23 per share, slightly worse than the Zacks Consensus Estimate of a $1.22 loss and wider than the $1.04 loss a year ago. The miss is small at $0.01 per share, making this a modest negative for earnings sentiment rather than a major fundamental shift.

Analysis

Crinetics Pharmaceuticals reported a quarterly loss of $1.23 per share, slightly worse than the Zacks Consensus Estimate of a $1.22 loss and wider than the $1.04 loss a year ago. The miss is small at $0.01 per share, making this a modest negative for earnings sentiment rather than a major fundamental shift.